Lazard Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-4,350
| Closed | -$123K | – | 2603 |
|
|
2023
Q1 | $123K | Sell |
4,350
-353
| -8% | -$9.98K | ﹤0.01% | 1456 |
|
|
2022
Q4 | $137K | Buy |
4,703
+373
| +9% | +$10.9K | ﹤0.01% | 1403 |
|
|
2022
Q3 | $114K | Hold |
4,330
| – | – | ﹤0.01% | 1422 |
|
|
2022
Q2 | $192K | Buy |
4,330
+1,926
| +80% | +$85.4K | ﹤0.01% | 1295 |
|
|
2022
Q1 | $118K | Sell |
2,404
-1
| -0% | -$49 | ﹤0.01% | 1354 |
|
|
2021
Q4 | $122K | Buy |
2,405
+248
| +11% | +$12.6K | ﹤0.01% | 1388 |
|
|
2021
Q3 | $120K | Buy |
+2,157
| New | +$120K | ﹤0.01% | 1376 |
|
|
2021
Q1 | – | Sell |
-1,610
| Closed | -$74K | – | 2068 |
|
|
2020
Q4 | $74K | Buy |
1,610
+1,487
| +1,209% | +$68.3K | ﹤0.01% | 1267 |
|
|
2020
Q3 | $5K | Sell |
123
-1,154
| -90% | -$46.9K | ﹤0.01% | 1546 |
|
|
2020
Q2 | $61K | Buy |
+1,277
| New | +$61K | ﹤0.01% | 1174 |
|
|
2018
Q3 | – | Sell |
-322,340
| Closed | -$24.4M | – | 1122 |
|
|
2018
Q2 | $24.4M | Sell |
322,340
-1,917
| -0.6% | -$145K | 0.04% | 275 |
|
|
2018
Q1 | $17.1M | Sell |
324,257
-43,240
| -12% | -$2.28M | 0.03% | 330 |
|
|
2017
Q4 | $19.6M | Buy |
367,497
+15,824
| +4% | +$845K | 0.03% | 309 |
|
|
2017
Q3 | $21M | Buy |
351,673
+73,391
| +26% | +$4.38M | 0.04% | 278 |
|
|
2017
Q2 | $22M | Buy |
278,282
+254,007
| +1,046% | +$20M | 0.04% | 280 |
|
|
2017
Q1 | $2.01M | Sell |
24,275
-9,125
| -27% | -$757K | ﹤0.01% | 654 |
|
|
2016
Q4 | $2.65M | Hold |
33,400
| – | – | 0.01% | 602 |
|
|
2016
Q3 | $2.34M | Hold |
33,400
| – | – | ﹤0.01% | 611 |
|
|
2016
Q2 | $1.3M | Buy |
+33,400
| New | +$1.3M | ﹤0.01% | 667 |
|